Small-Cap S-1 Bundle: Dare Bioscience, RZ Wellness

Analysis

Two small-cap SEC filings this week illustrate just how wide the range is within a single week's S-1 pipeline. Dare Bioscience, Inc. entered a securities purchase agreement on August 14, 2026 with institutional investors through a registered direct offering and private placement, issuing Series A and Series B warrants to purchase up to an aggregate of 4.38 million shares of common stock each. The company then filed an S-1 registering the resale of shares issuable upon exercise of those warrants, as required under the terms of the placement. Dare's Nasdaq-listed common stock, ticker DARE, last closed at $0.80 per share as of August 24, 2026.

At the opposite end of the scale, RZ Wellness Limited amended its S-1 on August 26 to sell 5.5 million shares at 3 cents apiece, a $165,000 total raise headed for the OTCQB Venture Market -- among the smallest public offerings on record by dollar size. The company, incorporated in Nevada with its principal business address in Petaling Jaya, Selangor, Malaysia, operates in the wholesale drugs, proprietaries and druggists' sundries industry. Nicole Chia Tzu Hsuan, appointed CEO, CFO, President, Treasurer, Secretary and Director in January 2026, is the company's sole employee, devoting roughly 30 hours per week to its operations.

Neither filing represents a marquee operating-company debut -- Dare is registering resale shares from an existing warrant structure at a company already trading below $1, and RZ Wellness's entire offering size is smaller than a single seed check most venture-backed startups would consider modest. Read together, they're a useful reminder of how much SEC filing volume in any given week spans genuinely tiny, thinly capitalized entities alongside the billion-dollar IPOs and acquisitions dominating headlines -- and why checking a filing's actual dollar terms matters more than reacting to the S-1 label alone.